Phase Scientific
Phase Scientific is a Hong Kong-headquartered diagnostics company (UCLA spin-out, founded 2015) that has commercialized PHASIFY™, a proprietary urine concentration technology enabling non-invasive biomarker-based testing for cancer screening, women's health, and infectious disease detection across 30+ countries.
- Company typePrivate
- Founded2015
- HeadquartersKowloon City, Hong Kong SAR China
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Phase Scientific does
Phase Scientific is a privately held biotechnology company founded in 2015 as a spin-out from UCLA, headquartered at Hong Kong Science Park with cross-border operations spanning Southern California and Shenzhen's Greater Bay Area. The company has built its business around PHASIFY™, a proprietary urine concentration technology that captures biomarkers at over 10x the sensitivity of industry gold standards, enabling non-invasive sample collection for diagnostic applications spanning cancer early screening, women's health, respiratory infections, gastrointestinal disease, and sexual health. The technology platform underpins a portfolio of over 30 commercialized diagnostic products, including the INDICAID® rapid antigen test line (originally COVID-focused), PhaseLab™ HPV urine detection for cervical cancer screening (demonstrating 93.4% sensitivity for CIN2+ lesions and over 97% concordance with Roche Cobas 4800 for HPV 16/18 detection), and FebriDx®, a rapid point-of-care test differentiating bacterial from non-bacterial respiratory infections.
The company monetizes through multiple revenue streams: direct sales of diagnostic test products (over 100 million test products delivered globally to date across 30+ countries), laboratory testing services through wholly-owned subsidiaries PhaseLab (相达医学) and Onco Medical Laboratory (安球医学化验所) which have collectively conducted over 8 million tests, and channel partnerships. Phase Scientific operates as the exclusive US distributor for FebriDx under a $317 million, 6-year distribution agreement with Lumos Diagnostics, with milestone pre-payments totaling US$7.5 million already paid. Following FDA 510(k) clearance and a March 2026 CLIA waiver, the company has activated commercial infrastructure to deploy FebriDx across over 300,000 US Certificate of Waiver facilities, supported by a CMS reimbursement rate of $41.38 per test. The customer base spans urgent care centers, retail health clinics, hospital systems, and public health screening programs, with go-to-market executed through direct enterprise field sales, clinical research partnerships (notably with Beijing University Shenzhen Hospital on a 17,000-women cervical cancer screening study), and regional distribution agreements.
Phase Scientific firmographics
Firmographics- Name
- Phase Scientific
- Legal name
- PHASE Scientific International Limited
- Website
- https://phasescientific.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Phase Scientific is a Hong Kong-headquartered diagnostics company (UCLA spin-out, founded 2015) that has commercialized PHASIFY™, a proprietary urine concentration technology enabling non-invasive biomarker-based testing for cancer screening, women's health, and infectious disease detection across 30+ countries.
- Ownership category
- akta.pro rank
Phase Scientific industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Urinalysis & Routine Screening Diagnostics (HLAHAAAG)
- akta.pro secondary industries
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)
Keywords
Where Phase Scientific is headquartered
LocationHeadquarters
- HQ city
- Kowloon City
- HQ country
- Hong Kong SAR China
- HQ region
- Asia
Offices3 records
Markets served
Phase Scientific business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others
Revenue model
- Diagnostic Test Products: Sale of over 30 innovative diagnostic products across respiratory, gastrointestinal, women's health, sexual health, pediatric health, and oncology. Over 100 million test products delivered globally to date.
- Laboratory Testing Services: Over 8 million laboratory tests conducted, generating revenue from laboratory service fees.
- Distribution Agreement Revenue: Revenue from distribution agreements including milestone pre-payments and product order payments. Total pre-payments from Phase Scientific to Lumos Diagnostics reached US$7.5 million under the FebriDx distribution agreement.
- FebriDx US Distribution: Commercial deployment of FebriDx point-of-care test across US healthcare settings following FDA CLIA waiver, with reimbursement secured at $41.38 per test from CMS.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | FebriDx test reimbursement |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
Phase Scientific product offering
Product offeringCore offering
Phase Scientific develops and commercializes proprietary urine-based diagnostic tests built on its PHASIFY™ urine concentration technology platform, which captures biomarker detection sensitivity over 10x the industry gold standard. The company sells a portfolio of 30+ diagnostic products — including the INDICAID® rapid antigen tests, PhaseLab™ HPV Urine Detection for cervical cancer screening, and the FDA-cleared FebriDx® point-of-care respiratory infection test — and provides clinical laboratory testing services through its PhaseLab and Onco Medical Laboratory subsidiaries.
Product overview
Phase Scientific is a biotechnology company that has developed PHASIFY™ as its core proprietary urine concentration technology platform, which captures biomarker detection sensitivity over 10x the industry gold standard. The company offers a portfolio of diagnostic products including INDICAID rapid tests, PhaseLab™ HPV urine detection for cervical cancer screening, and FebriDx® for point-of-care respiratory infection differentiation. The PHASIFY technology platform serves as the foundation enabling multiple product lines spanning cancer early screening, women's health, and infectious disease diagnostics, all based on non-invasive urine sample collection.
Differentiator
Problem solved
Functional benefit
Products and services
- PHASIFY™ Proprietary urine concentration technology platform that captures biomarker detection sensitivity at over 10 times the industry gold standard, enabling non-invasive early disease detection through liquid biopsy diagnostics. Forms the foundational IP underlying the company's diagnostic products.
- INDICAID® (妥析) Brand name under which Phase Scientific offers point-of-care diagnostic products including rapid antigen tests, distributed across multiple countries for infectious disease detection.
- PhaseLab™ HPV Urine Detection Next-generation urine-based HPV DNA detection system for cervical cancer screening; in clinical studies demonstrated over 97% concordance with standard physician-collected samples for HPV 16/18 detection and 93.4% sensitivity for CIN2+ lesions.
- FebriDx® Rapid point-of-care test that differentiates bacterial from non-bacterial respiratory infections; received FDA 510(k) clearance and CLIA waiver, enabling use across over 300,000 US healthcare settings including urgent care centers and retail health clinics.
- PhaseLab (相达医学) Laboratory testing services brand offering clinical diagnostic testing services using Phase Scientific's proprietary technologies; over 8 million laboratory tests conducted to date.
- Onco Medical Laboratory (安球医学化验所) Oncology-focused medical laboratory providing diagnostic testing services related to cancer screening and detection.
Quantifiable outcome
- 93.4% sensitivity for CIN2+ lesions in cervical cancer screening using urine HPV testing
- +2 more outcomes
Companies that use Phase Scientific
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Phase Scientific technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Phase Scientific partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Shenzhen Media Public Welfare FoundationminorCharitable partnership for cervical cancer screening公益 program targeting 17,000 women in Guang'an region. Donation directed through 'Shenxin Public Welfare Fund' for grassroots female health screening initiatives using Phase Scientific's urine HPV testing technology.
- Lumos Diagnostics Holdings LtdcoreExclusive US distribution partnership for FebriDx point-of-care test with a $317 million, 6-year distribution agreement. Phase Scientific received milestone pre-payments totaling $7.5 million following FDA CLIA waiver, with commercial infrastructure built out for broad deployment.
- Beijing University Shenzhen HospitalcoreClinical research partner for urine HPV cervical cancer screening studies involving 17,000 women. Published clinical validation data showing 93.4% sensitivity for CIN2+ lesions and over 97% consistency with standard testing. Partner for SCOCCAPS study on cervical cancer prevention innovation model.
Scale indicators8 records
Recent moves7 records
Expansion highlights7 records
Phase Scientific competitors and assessment
Company assessmentEmerging players
- GRAIL: Multi-cancer early detection company developing Galleri blood-based screening test. Represents the strategic archetype Phase Scientific aims to compete with using urine-based PHASIFY technology, though GRAIL is much further along in clinical validation and commercialization.
- Exact Sciences: Commercial-stage cancer screening company behind Cologuard (CRC) and Oncotype DX. Represents the gold standard business model for non-invasive cancer screening that Phase Scientific's PHASIFY-based liquid biopsy aspirations aim to replicate in urine.
Broad incumbents
- Roche Diagnostics: Global diagnostics incumbent whose Cobas 4800 HPV test is the gold standard that PhaseLab HPV Urine Detection demonstrated 97% concordance with. Operates broadly across IVD, molecular diagnostics, and women's health with significantly larger scale and clinical evidence base.
- Abbott Diagnostics: Global diagnostics incumbent where Phase Scientific's CSO previously served 18 years. Competes across rapid diagnostics, core laboratory, molecular, and point-of-care testing. Phase Scientific's positioning as a urine-based diagnostics innovator is partly built against Abbott's installed testing infrastructure.
Direct peers
- Cepheid (Danaher): Market leader in molecular point-of-care testing with GeneXpert systems deployed across US urgent care and hospital settings. Competes with FebriDx in respiratory infection differentiation and represents the dominant POCT benchmark Phase Scientific must displace at Certificate of Waiver facilities.
- Hologic: Leading women's health diagnostics company with the Aptima HPV testing franchise that competes directly with PhaseLab's urine-based HPV detection. Also operates in molecular diagnostics, cervical cancer screening, and infectious disease rapid testing — overlapping multiple Phase Scientific verticals.
- Lumos Diagnostics: Developer of FebriDx — the rapid point-of-care bacterial vs viral infection test for which Phase Scientific holds exclusive US distribution rights under a $317M, 6-year agreement. Direct product/partner overlap makes Lumos both commercial partner and closest functional peer.
- QuidelOrtho: Specialized rapid diagnostics company with Sofia and Triage product lines for respiratory and infectious disease testing. Competes with both FebriDx in point-of-care respiratory infection differentiation and INDICAID rapid antigen tests, with similar US CLIA-waived distribution channels.
Regional players
- Sansure Biotech: China-based molecular diagnostics company where Phase Scientific's new CSO previously served as CTO. Competes in IVD reagents, infectious disease molecular testing, and cancer diagnostics across Greater China — the most direct regional comparison given overlapping leadership pedigree and product overlap.
- Burning Rock Biotech: China-based oncology diagnostics company specializing in next-generation sequencing for cancer therapy selection and minimal residual disease (MRD) testing. Directly comparable to Onco Medical Laboratory in targeting Chinese oncology diagnostics market with molecular approaches.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Phase Scientific social profiles
Digital presencePhase Scientific financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phase Scientific leadership team
Management profileNumber of profiles
Profiles12 records
Phase Scientific subsidiaries and ownership
Company hierarchySubsidiaries2 records
Phase Scientific funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phase Scientific M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phase Scientific
What does Phase Scientific do?
Phase Scientific develops and commercializes proprietary urine-based diagnostic tests built on its PHASIFY™ urine concentration technology platform, which captures biomarker detection sensitivity over 10x the industry gold standard. The company sells a portfolio of 30+ diagnostic products — including the INDICAID® rapid antigen tests, PhaseLab™ HPV Urine Detection for cervical cancer screening, and the FDA-cleared FebriDx® point-of-care respiratory infection test — and provides clinical laboratory testing services through its PhaseLab and Onco Medical Laboratory subsidiaries.
Is Phase Scientific a public or private company?
Phase Scientific is a private company. It is classified as venture growth investor backed and is currently operating.
When was Phase Scientific founded?
Phase Scientific was founded in 2015. It employs 101 to 250 people.
Where is Phase Scientific based?
Phase Scientific is headquartered in Kowloon City, Hong Kong SAR China, in the Asia region.
How does Phase Scientific make money?
Four revenue lines are on record. Diagnostic Test Products are the primary driver. The others are laboratory Testing Services, distribution Agreement Revenue and febriDx US Distribution.
Who are Phase Scientific's main competitors?
Emerging players on record are GRAIL and Exact Sciences. Broad incumbents are Roche Diagnostics and Abbott Diagnostics. Direct peers are Cepheid (Danaher), Hologic, Lumos Diagnostics and QuidelOrtho. Regional players are Sansure Biotech and Burning Rock Biotech.
Does Phase Scientific have an API?
No public API is recorded for Phase Scientific.
What industry is Phase Scientific in?
Phase Scientific's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAG, Urinalysis & Routine Screening Diagnostics, with a secondary code of HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing. Its NAICS code is 325413 and its SIC code is 2835.